Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:03:11.951Z.
Calculation as of: 2026-10-06T16:03:11.951Z.
Quote observation: 2026-10-06T15:59:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b6268879a98e6c39cef7c3f9e2e80a63ea5355fd191f52e510f01db01fc6dd59
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Greenwich LifeSciences, Inc.
Market Cap
$243.66M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$243.81M
EBITDA Yield
N/A
TTM Avg
3.52%
3Y Avg
3.58%
5Y Avg
4.02%
Market Cap
$240.82M
EBITDA Yield
N/A
TTM Avg
6.75%
3Y Avg
3.64%
5Y Avg
3.64%
Market Cap
$240.66M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | $243.66M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.81M | N/A | 3.52% | 3.58% | 4.02% |
| Galectin Therapeutics Inc. (GALT)vs › | $243.34M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $244.64M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $240.82M | N/A | 6.75% | 3.64% | 3.64% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.66M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $240.09M | N/A | N/A | N/A | N/A |
| Q32 Bio Inc. (QTTB)vs › | $246.59M | 15.04% | 32.49% | 32.49% | 32.49% |
| Century Therapeutics, Inc. (IPSC)vs › | $248.98M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $237.25M | 7.81% | 5.41% | 5.10% | 3.84% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
